TDOC — Teladoc Health Income Statement
0.000.00%
- $1.26bn
- $1.51bn
- $2.57bn
- 61
- 75
- 18
- 51
Annual income statement for Teladoc Health, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 1,094 | 2,033 | 2,407 | 2,602 | 2,570 |
Cost of Revenue | |||||
Gross Profit | 703 | 1,382 | 1,663 | 1,842 | 1,818 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 1,609 | 2,342 | 16,060 | 2,851 | 3,590 |
Operating Profit | -515 | -309 | -13,653 | -249 | -1,021 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -576 | -385 | -13,663 | -220 | -994 |
Provision for Income Taxes | |||||
Net Income After Taxes | -485 | -429 | -13,660 | -220 | -1,001 |
Net Income Before Extraordinary Items | |||||
Net Income | -485 | -429 | -13,660 | -220 | -1,001 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -485 | -429 | -13,660 | -220 | -1,001 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -4.66 | -2.44 | -30.6 | -1.19 | -2.78 |